{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:10:39Z","timestamp":1791612639775,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,2]],"date-time":"2027-01-02T00:00:00Z","timestamp":1798848000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014434","name":"Irving Medical Center, Columbia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007161","name":"Boston University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-016520"],"award-info":[{"award-number":["P30-016520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017006","name":"Abramson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021051","name":"Cabaletta Bio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.kint.2025.09.028","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:42:54Z","timestamp":1761928974000},"page":"89-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells"],"prefix":"10.1016","volume":"109","author":[{"given":"Burcin","family":"Altun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-6089","authenticated-orcid":false,"given":"Gexin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baomei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuming","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Manfredo-Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma E.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina C.","family":"Boesteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar I.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshil R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony","family":"Cottman-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.09.028_bib1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.028_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.028_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.028_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1681\/ASN.0000000000000068","article-title":"Pathogenicity of human anti-PLA 2 R1 antibodies in minipigs: a pilot study","volume":"34","author":"Reinhard","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.028_bib5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","article-title":"Rituximab in idiopathic membranous nephropathy: a one-year prospective study","volume":"14","author":"Ruggenenti","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.028_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.028_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adm8186","article-title":"Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-\u03b3","volume":"10","author":"Peng","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.kint.2025.09.028_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2018.04.006","article-title":"La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease","volume":"192","author":"Meng","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.kint.2025.09.028_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.028_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.kint.2025.09.028_bib11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.kint.2025.09.028_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt0795","article-title":"Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis","volume":"11","author":"Oh","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.kint.2025.09.028_bib13","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.kint.2025.09.028_bib14","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.09.028_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.028_bib16","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.028_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.028_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.028_bib19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nature03843","article-title":"T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand","volume":"436","author":"Choudhuri","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.kint.2025.09.028_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.028_bib21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3389\/fimmu.2020.00837","article-title":"Phospholipase A2 receptor autoantibodies as a novel serological biomarker for autoimmune thyroid disease associated nephropathy","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Immunol"},{"key":"10.1016\/j.kint.2025.09.028_bib22","article-title":"Ultrasensitive quantitation of anti-phospholipase A2 receptor antibody as a diagnostic and prognostic indicator of idiopathic membranous nephropathy","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2025.09.028_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40001-023-01096-5","article-title":"The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy","volume":"28","author":"Cheng","year":"2023","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.kint.2025.09.028_bib24","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.celrep.2018.04.059","article-title":"A multi-layered quantitative in vivo expression atlas of the podocyte unravels kidney disease candidate genes","volume":"23","author":"Rinschen","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.kint.2025.09.028_bib25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.kint.2019.10.022","article-title":"A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients","volume":"97","author":"Meyer-Schwesinger","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.028_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2022.09.008","article-title":"Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice","volume":"103","author":"Tomas","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.028_bib27","first-page":"e138","article-title":"Correlative findings following DSG3-CAART infusion with & without combination preconditioning therapy in patients with Pemphigus Vulgaris (DesCAARTes study)","volume":"36","author":"Volkov","year":"2025","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.kint.2025.09.028_bib28","first-page":"e451","article-title":"Clinical and translational findings following MuSK-CAART infusion without preconditioning in patients with myasthenia gravis (MuSCAARTesTM trial)","volume":"36","author":"Volkov","year":"2025","journal-title":"Hum Gene Ther"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:31:40Z","timestamp":1778941900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825008555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0085253825008555"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.028","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.10.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}